{"id":"folfox-2d","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Neuropathy (peripheral)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Mucositis"}]},"_chembl":{"chemblId":"CHEMBL3686108","moleculeType":"Small molecule","molecularWeight":"429.48"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FOLFOX is a combination chemotherapy regimen where 5-fluorouracil (5-FU) inhibits thymidylate synthase to disrupt DNA synthesis, leucovorin enhances 5-FU activity by stabilizing its binding to the enzyme, and oxaliplatin is a platinum agent that forms DNA cross-links. The '2d' designation indicates a modified 2-day infusion schedule variant of the standard FOLFOX protocol, designed to optimize dosing and tolerability.","oneSentence":"FOLFOX 2d is a chemotherapy regimen combining 5-fluorouracil, leucovorin, and oxaliplatin administered on a modified 2-day schedule to inhibit DNA synthesis and induce apoptosis in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:11.562Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer (likely primary indication based on FOLFOX standard use)"}]},"trialDetails":[{"nctId":"NCT06917079","phase":"PHASE1","title":"BBO-11818 in Adult Subjects With KRAS Mutant Cancer","status":"RECRUITING","sponsor":"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)","startDate":"2025-03-31","conditions":"Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":387},{"nctId":"NCT06154538","phase":"PHASE2","title":"Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-11-01","conditions":"Locally Advanced Colorectal Carcinoma","enrollment":170},{"nctId":"NCT06576037","phase":"PHASE1","title":"Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-10-31","conditions":"Solid Tumor","enrollment":128},{"nctId":"NCT05797883","phase":"PHASE2","title":"FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"China Medical University, China","startDate":"2022-08-01","conditions":"Unresectable or Metastatic Colorectal Cancer","enrollment":30},{"nctId":"NCT05476432","phase":"PHASE3","title":"HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-07-26","conditions":"Hepatocellular Carcinoma","enrollment":300},{"nctId":"NCT05074966","phase":"PHASE3","title":"The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2021-09-06","conditions":"Colo-rectal Cancer","enrollment":314},{"nctId":"NCT04198051","phase":"NA","title":"The Clinical Study of Adjuvant Chemotherapy on Intestinal and Urethral Flora in Patients With Gastric and Colon Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Dalian Medical University","startDate":"2019-12-20","conditions":"Gastric Cancer, Colon Cancer","enrollment":120},{"nctId":"NCT01763450","phase":"PHASE2","title":"Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer","status":"UNKNOWN","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2012-09","conditions":"Liver Metastases, Colorectal Cancer","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"FOLFOX 2d","genericName":"FOLFOX 2d","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FOLFOX 2d is a chemotherapy regimen combining 5-fluorouracil, leucovorin, and oxaliplatin administered on a modified 2-day schedule to inhibit DNA synthesis and induce apoptosis in cancer cells. Used for Colorectal cancer (likely primary indication based on FOLFOX standard use).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}